Barclays’s American Renal Associates Holdings, Inc ARA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-4,636
| Closed | -$53K | – | 5392 |
|
|
2020
Q4 | $53K | Sell |
4,636
-1,934
| -29% | -$22K | ﹤0.01% | 4380 |
|
|
2020
Q3 | $46K | Sell |
6,570
-2,260
| -26% | -$14.8K | ﹤0.01% | 4654 |
|
|
2020
Q2 | $57K | Sell |
8,830
-851
| -9% | -$5.49K | ﹤0.01% | 4870 |
|
|
2020
Q1 | $65K | Sell |
9,681
-12,266
| -56% | -$107K | ﹤0.01% | 5068 |
|
|
2019
Q4 | $227K | Buy |
21,947
+6,277
| +40% | +$53.7K | ﹤0.01% | 4941 |
|
|
2019
Q3 | $99K | Sell |
15,670
-3,357
| -18% | -$25K | ﹤0.01% | 5491 |
|
|
2019
Q2 | $142K | Buy |
19,027
+14,768
| +347% | +$97.4K | ﹤0.01% | 5410 |
|
|
2019
Q1 | $26K | Sell |
4,259
-9,078
| -68% | -$105K | ﹤0.01% | 6253 |
|
|
2018
Q4 | $153K | Sell |
13,337
-55,817
| -81% | -$952K | ﹤0.01% | 4771 |
|
|
2018
Q3 | $1.5M | Buy |
69,154
+14,624
| +27% | +$277K | ﹤0.01% | 3231 |
|
|
2018
Q2 | $860K | Buy |
54,530
+2,235
| +4% | +$35.1K | ﹤0.01% | 3449 |
|
|
2018
Q1 | $986K | Buy |
52,295
+10,093
| +24% | +$199K | ﹤0.01% | 3233 |
|
|
2017
Q4 | $734K | Buy |
42,202
+41,933
| +15,588% | +$579K | ﹤0.01% | 3430 |
|
|
2017
Q3 | $4K | Sell |
269
-25,976
| -99% | -$408K | ﹤0.01% | 6542 |
|
|
2017
Q2 | $488K | Sell |
26,245
-12,674
| -33% | -$220K | ﹤0.01% | 3556 |
|
|
2017
Q1 | $657K | Buy |
38,919
+22,611
| +139% | +$451K | ﹤0.01% | 3132 |
|
|
2016
Q4 | $347K | Buy |
16,308
+16,253
| +29,551% | +$333K | ﹤0.01% | 3699 |
|
|
2016
Q3 | $1K | Buy |
+55
| New | +$1.24K | ﹤0.01% | 6502 |
|
Barclays's ARA Position: Q1 2021 in Review
Barclays sold out of American Renal Associates Holdings, Inc (ARA) in Q1 2021, closing a stake of 4,636 shares — an estimated $53K sold.
Barclays first reported a position in ARA in Q3 2016 and held it in 18 quarters. The position peaked at $1.5M in Q3 2018. 0 funds tracked by Wall St. Rank hold ARA as of Q1 2021.
- Barclays reported no remaining American Renal Associates Holdings, Inc position as of Q1 2021 after selling out during the quarter.
- Barclays sold 4,636 American Renal Associates Holdings, Inc shares in Q1 2021, an estimated $53K.
- Barclays first reported a position in American Renal Associates Holdings, Inc in Q3 2016 and held it in 18 quarters.
- Barclays's American Renal Associates Holdings, Inc position peaked at $1.5M in Q3 2018.
- 0 funds tracked by Wall St. Rank held American Renal Associates Holdings, Inc as of Q1 2021.
Based on Barclays's 13F filing for Q1 2021, filed 13 May 2021.